Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993974 | 0.97 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL1206740 | 0.94 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL29060008 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL18551726 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL29060009 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL4117938 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL21405300 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL4111065 | 0.87 | HTT (0.65) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL7398151 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL28809437 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| CN-117858874-A | HPK1 degrading agents, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116199685-A | HER2 degradation agent and application thereof | 四川海思科制药有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| CN-112543764-A | Amide compound with BET proteolysis induction effect and medical application thereof | 田边三菱制药株式会社 | 2021-03-23 | — | — | CN | disclosed |
| US-5612373-A | ANTICOAGULANTS | ZENECA LIMITED (GB) | 1997-03-18 | — | — | US | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| US-5545658-A | FOR TREATMENT OR PROPHYLAXIS OF ILLNESSES WHICH ARE CAUSED BY THE BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELETS AND BY BLOOD PLATELET AGGREGATION AND CELL-CELL ADHESION | HOFFMAN-LA ROCHE INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| EP-0505868-B1 | N-Acyl-alpha-aminoacids derivatives | HOFFMANN LA ROCHE (CH) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995000472-A1 | 1,2 DIACYLATED HYDRAZINE DERIVATIVES AND THEIR USE AS ALL ADHESION INHIBITORS | ZENECA LIMITED (GB) | 1995-01-05 | — | — | WO | disclosed |
| EP-0632016-A1 | 1,2-Diacylated hydrazine derivatives and their use as cell adhesion inhibitors | ZENECA LIMITED (GB) | 1995-01-04 | — | — | EP | disclosed |
| US-5378712-A | Antithrombosis | Hoffmann-La Roche Inc (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0505868-A2 | N-Acyl-alpha-aminoacids derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | HYPK, PGK1, HIPK1 | SMN1; SMN2 2070/4885NPC1 1056/4885RAB9A 3197/4885 |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | SMN1; SMN2 4500/4885NPC1 3288/4885RAB9A 2761/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | SMN1; SMN2 4459/4885NPC1 3072/4885RAB9A 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.